HAVCR2 and hepatocellular carcinoma: These methods include using neoantigen immunotherapy gel combined with Tim-3 blockade (17), co-delivering Tim-3 siRNA and sorafenib via nanoparticles (18), and blocking Tim-3 signaling to prevent CD8+ T cell apoptosis (19), thereby enhancing the anti-HCC effect.